A High-Throughput Functional Complementation Assay for Classification of <i>BRCA1</i> Missense Variants

Peter Bouwman(Cancer Genomics Centre), Hanneke van der Gulden(Cancer Genomics Centre), Ingrid van der Heijden(Cancer Genomics Centre), Rinske Drost(Cancer Genomics Centre), Christiaan Klijn(Cancer Genomics Centre), Pramudita R. Prasetyanti(Cancer Genomics Centre), Mark Pieterse(Cancer Genomics Centre), Ellen Wientjens(Cancer Genomics Centre), Jost Seibler(Cancer Genomics Centre), Frans B.L. Hogervorst(Cancer Genomics Centre), Jos Jonkers(Cancer Genomics Centre)
Cancer Discovery
July 19, 2013
Cited by 137

Abstract

UNLABELLED: Mutations in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian cancers, and therefore sequence analysis of both genes is routinely conducted in patients with early-onset breast cancer. Besides mutations that clearly abolish protein function or are known to increase cancer risk, a large number of sequence variants of uncertain significance (VUS) have been identified. Although several functional assays for BRCA1 VUSs have been described, thus far it has not been possible to conduct a high-throughput analysis in the context of the full-length protein. We have developed a relatively fast and easy cDNA-based functional assay to classify BRCA1 VUSs based on their ability to functionally complement BRCA1-deficient mouse embryonic stem cells. Using this assay, we have analyzed 74 unclassified BRCA1 missense mutants for which all predicted pathogenic variants are confined to the BRCA1 RING and BRCT domains. SIGNIFICANCE: BRCA1 VUSs are frequently found in patients with hereditary breast or ovarian cancer and present a serious problem for clinical geneticists. This article describes the generation, validation, and application of a reliable high-throughput assay for the functional classification of BRCA1 sequence variants of uncertain significance.


Related Papers

No related papers found

Powered by citation graph analysis